These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10912121)

  • 1. [Thrombosis ABC, 5: No prophylaxis without bleeding risk. Safe navigation between Scylla and Charybdis].
    Stiefelhagen P
    MMW Fortschr Med; 1999 Oct; 141(43):42. PubMed ID: 10912121
    [No Abstract]   [Full Text] [Related]  

  • 2. [The value of laboratory diagnosis in thrombolytic therapy].
    Ostermann H; Kienast J
    Internist (Berl); 1992 Apr; 33(4):252-7. PubMed ID: 1612849
    [No Abstract]   [Full Text] [Related]  

  • 3. New oral antithrombotics: a need for laboratory monitoring. For.
    Mismetti P; Laporte S
    J Thromb Haemost; 2010 Apr; 8(4):621-6. PubMed ID: 20102486
    [No Abstract]   [Full Text] [Related]  

  • 4. New oral antithrombotics: a need for laboratory monitoring. Against.
    Bounameaux H; Reber G
    J Thromb Haemost; 2010 Apr; 8(4):627-30. PubMed ID: 20088926
    [No Abstract]   [Full Text] [Related]  

  • 5. Antithrombotic agents and invasive procedures--hematologist point of view.
    Lecompte TP
    Thromb Res; 2012 Oct; 130 Suppl 1():S61-2. PubMed ID: 23026666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    May AE; Geisler T; Gawaz M
    Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage.
    Crowther M; Crowther M
    Expert Rev Hematol; 2009 Aug; 2(4):357-60. PubMed ID: 21082940
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemostasis and coagulation monitoring and management during liver transplantation.
    Dalmau A; Sabaté A; Aparicio I
    Curr Opin Organ Transplant; 2009 Jun; 14(3):286-90. PubMed ID: 19300254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quick reference guide to the new oral anticoagulants.
    Hurst K; Lee R; Handa A
    J Vasc Surg; 2016 Jun; 63(6):1653-7. PubMed ID: 27113315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Perioperative thrombosis prophylaxis - thrombosis or bleeding - that is the question].
    Ellger B; Van Aken HK
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2012 Apr; 47(4):240-1. PubMed ID: 22504620
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a fine balance between thrombosis and bleeding.
    Ghattas A; Shantsila E; Lip GY
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):5-9. PubMed ID: 21282200
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood coagulation: hemostasis and thrombin regulation.
    Tanaka KA; Key NS; Levy JH
    Anesth Analg; 2009 May; 108(5):1433-46. PubMed ID: 19372317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose of aspirin and bleeding risks.
    Serebruany V
    Am J Cardiol; 2006 Jul; 98(2):275. PubMed ID: 16828608
    [No Abstract]   [Full Text] [Related]  

  • 14. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
    Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
    Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of hirudins in percutaneous coronary intervention and the risk of Kounis syndrome.
    Kounis NG; Kounis SA; Kounis GN; Hahalis G
    Catheter Cardiovasc Interv; 2009 Mar; 73(4):584-5. PubMed ID: 19085914
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Thrombosis prophylaxis with new anticoagulants: Routine and specific risk groups.
    Kozek-Langenecker SA
    Wien Med Wochenschr; 2011 Feb; 161(3-4):53. PubMed ID: 21404138
    [No Abstract]   [Full Text] [Related]  

  • 17. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
    Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G; Casaní L; Badimon L
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.